Portal de Periódicos da CAPES

Two Years Postconversion From a Prograf-Based Regimen to a Once-Daily Tacrolimus Extended-Release Formulation in Stable Kidney Transplant Recipients

2007; Wolters Kluwer; Volume: 83; Issue: 12 Linguagem: Inglês

10.1097/01.tp.0000264056.20105.b4

1534-6080

Rita R. Alloway, Steven Steinberg, Kassem Khalil, Sita Gourishankar, Joshua Miller, Douglas J. Norman, Sundaram Hariharan, John D. Pirsch, Arthur J. Matas, Jeffrey S. Zaltzman, K. Wisemandle, William E. Fitzsimmons, M. Roy First,

Pharmacological Effects and Toxicity Studies

Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.